Ignite Creation Date:
2024-05-06 @ 3:59 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04838405
Status:
COMPLETED
Last Update Posted:
2022-07-26
First Post:
2021-04-05
Brief Title:
A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus
Sponsor:
Carmot Therapeutics Inc
Organization:
Carmot Therapeutics Inc
Study Overview
Official Title:
A Phase 1 Randomized Double Blind Placebo Controlled Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CT-388 in Otherwise Healthy Overweight and Obese Adult Participants and in Obese Patients With Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a first-in-human evaluation of CT-388 in a double blind placebo controlled randomized SADMADMD safety tolerance PK and PD study when administered as a SC injection in otherwise healthy overweight and obese adult participants and obese participants with T2DM
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None